Changes in prostate-specific antigen, markers of bone metabolism and bone scans after treatment with radium-223

References

• Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213–23.
   PubMed Web of Science ®Google Scholar
• Pandit-Taskar N, Larson SM, Carrasquillo JA. Bone-seeking radiopharmaceuticals for treatment of osseous metastases, Part 1: alpha therapy with 223Ra-dichloride. J Nucl Med 2014;55:268–74.
   PubMed Web of Science ®Google Scholar
• Lorente JA, Valenzuela H, Morote J, Gelabert A. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients. Eur J Nucl Med 1999;26:625–32.
   PubMedGoogle Scholar
• Kamiya N, Suzuki H, Endo T, Yano M, Naoi M, Nishimi D, et al. Clinical usefulness of bone markers in prostate cancer with bone metastasis. Int J Urol 2012;19:968–79.
   PubMed Web of Science ®Google Scholar
• Soloway MS, Hardeman SW, Hickey D, Raymond J, Todd B, Soloway S, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988;61:195–202.
   PubMed Web of Science ®Google Scholar
• Nanni C, Schiavina R, Brunocilla E, Borghesi M, Ambrosini V, Zanoni L, et al. 18F-FACBC compared with 11C-choline PET/CT in patients with biochemical relapse after radical prostatectomy: a prospective study in 28 patients. Clin Genitourin Cancer 2014;12:106–10.
   PubMed Web of Science ®Google Scholar
• Smeland S, Erikstein B, Aas M, Skovlund E, Hess SL, Fossa SD. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study. Int J Radiat Oncol Biol Phys 2003;56:1397–404.
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995–2005.
   PubMed Web of Science ®Google Scholar
• Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187–97.
   PubMed Web of Science ®Google Scholar
• Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev 2001;27:187–92.
   PubMed Web of Science ®Google Scholar
• Nilsson S, Franzen L, Parker C, Tyrrell C, Blom R, Tennvall J, et al. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 2007;8:587–94.
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Pond GR, Berry WR, de Wit R, Armstrong AJ, Eisenberger MA, et al. Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol 2012;30:607–13.
   PubMed Web of Science ®Google Scholar
• Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M, et al. Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 2000;26:367–73.
   PubMed Web of Science ®Google Scholar
• Silberstein EB. Teletherapy and radiopharmaceutical therapy of painful bone metastases. Semin Nucl Med 2005;35:152–8.
   PubMedGoogle Scholar
• Cook GJr, Parker C, Chua S, Johnson B, Aksnes AK, Lewington VJ. 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin). EJNMMI Res 2011;1:4.
   PubMed Web of Science ®Google Scholar
• Fossa SD, Heilo A, Lindegaard M, Skinningrud A, Ous S. Clinical significance of routine follow-up examinations in patients with metastatic cancer of the prostate under hormone treatment. Eur Urol 1983;9:262–6.
   PubMedGoogle Scholar
• Croke J, Leung E, Segal R, Malone S. Clinical benefits of Alpharadin in castrate-chemotherapy-resistant prostate cancer: case report and literature review. BMJ Case Rep 2012;2012:12
   Google Scholar
• Parker CC, Pascoe S, Chodacki A, O’Sullivan JM, Germa JR, O’Bryan-Tear CG, et al. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer. Eur Urol 2013;63:189–97.
   PubMed Web of Science ®Google Scholar